GSK-3β Inhibitor I (CAS 327036-89-5)
See product citations (4)
QUICK LINKS
GSK-3β Inhibitor I is a small molecule inhibitor specifically designed to target and inhibit glycogen synthase kinase-3 beta (GSK-3β), a serine/threonine kinase involved in a multitude of cellular processes including metabolism, cell division, and gene expression. This enzyme is known for its role in the Wnt signaling pathway and its implication in the regulation of glycogen synthesis. The mechanism by which GSK-3β Inhibitor I acts involves the competitive inhibition of ATP binding to the kinase′s active site. This inhibition disrupts the kinase′s ability to phosphorylate its substrates, which include numerous proteins involved in cell signaling pathways. By preventing these phosphorylation events, the inhibitor can modulate various signaling pathways, notably those related to cell growth and development. In scientific research, GSK-3β Inhibitor I has been extensively used to study the role of GSK-3β in cellular signaling and function. The compound allows researchers to dissect the kinase′s involvement in the Wnt/β-catenin pathway and its effects on cellular responses such as cell proliferation and differentiation.
GSK-3β Inhibitor I (CAS 327036-89-5) References
- What do insulin, estrogen, valproic acid, and TDZD-8 have in common? | Fink, MP. 2005. Crit Care Med. 33: 2115-7. PMID: 16148489
- Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). | Guzman, ML., et al. 2007. Blood. 110: 4436-44. PMID: 17785584
- Treatment with the glycogen synthase kinase-3beta inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus. | Collino, M., et al. 2008. Shock. 30: 299-307. PMID: 18323734
- Inhibition of glioblastoma growth by the thiadiazolidinone compound TDZD-8. | Aguilar-Morante, D., et al. 2010. PLoS One. 5: e13879. PMID: 21079728
- Activation of AKT/GSK3β pathway by TDZD-8 attenuates kainic acid induced neurodegeneration but not seizures in mice. | Bhowmik, M., et al. 2015. Neurotoxicology. 46: 44-52. PMID: 25453207
- GSK-3β inhibitor TDZD-8 reduces neonatal hypoxic-ischemic brain injury in mice. | Huang, S., et al. 2017. CNS Neurosci Ther. 23: 405-415. PMID: 28256059
- The GSK3β inhibitor, TDZD-8, rescues cognition in a zebrafish model of okadaic acid-induced Alzheimer's disease. | Koehler, D., et al. 2019. Neurochem Int. 122: 31-37. PMID: 30392874
- TDZD-8 alleviates delayed neurological sequelae following acute carbon monoxide poisoning involving tau protein phosphorylation. | Su, C., et al. 2020. Inhal Toxicol. 32: 79-85. PMID: 32188325
- GSK-3β inhibitor TDZD-8 prevents reduction of aquaporin-1 expression via activating autophagy under renal ischemia reperfusion injury. | Liu, Q., et al. 2021. FASEB J. 35: e21809. PMID: 34314052
- Human umbilical cord-derived mesenchymal stem cell transplantation supplemented with curcumin improves the outcomes of ischemic stroke via AKT/GSK-3β/β-TrCP/Nrf2 axis. | Li, Y., et al. 2023. J Neuroinflammation. 20: 49. PMID: 36829224
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GSK-3β Inhibitor I, 5 mg | sc-221692 | 5 mg | $179.00 | |||
GSK-3β Inhibitor I, 25 mg | sc-221692A | 25 mg | $282.00 |